We’ve recently updated our valuation analysis.

Liquidia Valuation

Is LQDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LQDA?

Other financial metrics that can be useful for relative valuation.

LQDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue27.1x
Enterprise Value/EBITDA-8.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LQDA's PS Ratio compare to its peers?

The above table shows the PS ratio for LQDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.5x
HROW Harrow Health
5.1x22.2%US$448.3m
TARS Tarsus Pharmaceuticals
26x52.8%US$413.7m
SIGA SIGA Technologies
2.5x-6.6%US$544.0m
EOLS Evolus
4.4x21.8%US$621.0m
LQDA Liquidia
32.5x46.5%US$447.6m

Price-To-Sales vs Peers: LQDA is expensive based on its Price-To-Sales Ratio (32.5x) compared to the peer average (9.5x).


Price to Earnings Ratio vs Industry

How does LQDA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a

Price-To-Sales vs Industry: LQDA is expensive based on its Price-To-Sales Ratio (32.5x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is LQDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LQDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio32.5x
Fair PS Ratio11.9x

Price-To-Sales vs Fair Ratio: LQDA is expensive based on its Price-To-Sales Ratio (32.5x) compared to the estimated Fair Price-To-Sales Ratio (11.9x).


Share Price vs Fair Value

What is the Fair Price of LQDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LQDA ($6.94) is trading below our estimate of fair value ($52.72)

Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LQDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.94
US$13.14
+89.4%
39.3%US$20.00US$3.00n/a7
Jan ’24US$6.37
US$13.14
+106.3%
39.3%US$20.00US$3.00n/a7
Dec ’23US$5.31
US$13.14
+147.5%
39.3%US$20.00US$3.00n/a7
Nov ’23US$5.18
US$13.29
+156.5%
38.1%US$20.00US$3.00n/a7
Oct ’23US$5.44
US$13.29
+144.2%
38.1%US$20.00US$3.00n/a7
Sep ’23US$4.86
US$13.29
+173.4%
38.1%US$20.00US$3.00n/a7
Aug ’23US$4.97
US$12.86
+158.7%
31.0%US$17.00US$4.00n/a7
Jul ’23US$4.24
US$11.83
+179.1%
31.8%US$16.00US$4.00n/a6
Jun ’23US$3.89
US$11.83
+204.2%
31.8%US$16.00US$4.00n/a6
May ’23US$5.44
US$11.75
+116.0%
30.9%US$16.00US$6.00n/a4
Apr ’23US$7.14
US$11.75
+64.6%
30.9%US$16.00US$6.00n/a4
Mar ’23US$6.50
US$10.25
+57.7%
39.3%US$16.00US$6.00n/a4
Feb ’23US$6.00
US$7.75
+29.2%
32.1%US$12.00US$6.00n/a4
Jan ’23US$4.87
US$6.75
+38.6%
12.3%US$8.00US$6.00US$6.374
Dec ’22US$4.13
US$6.75
+63.4%
12.3%US$8.00US$6.00US$5.314
Nov ’22US$3.82
US$4.25
+11.3%
34.8%US$6.00US$2.00US$5.184
Oct ’22US$2.75
US$4.25
+54.5%
34.8%US$6.00US$2.00US$5.444
Sep ’22US$2.80
US$4.25
+51.8%
34.8%US$6.00US$2.00US$4.864
Aug ’22US$2.30
US$4.25
+84.8%
34.8%US$6.00US$2.00US$4.974
Jul ’22US$2.82
US$4.25
+50.7%
34.8%US$6.00US$2.00US$4.244
Jun ’22US$2.94
US$4.25
+44.6%
34.8%US$6.00US$2.00US$3.894
May ’22US$2.84
US$4.50
+58.5%
24.8%US$6.00US$3.00US$5.444
Apr ’22US$2.76
US$4.50
+63.0%
24.8%US$6.00US$3.00US$7.144
Mar ’22US$2.93
US$5.00
+70.6%
20.0%US$6.00US$4.00US$6.504
Feb ’22US$2.74
US$5.20
+89.8%
18.8%US$6.00US$4.00US$6.005
Jan ’22US$2.95
US$5.20
+76.3%
18.8%US$6.00US$4.00US$4.875

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies